🇺🇸 FDA
Pipeline program

Linvoseltamab

R5458-ONC-2257

Phase 2 small_molecule active

Quick answer

Linvoseltamab for Monoclonal Gammopathy of Undetermined Significance (MGUS) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials